Seer Inc - Asset Resilience Ratio
Seer Inc (SEER) has an Asset Resilience Ratio of 43.86% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Seer Inc's Asset Resilience Ratio has changed over time. Check SEER PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Seer Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Seer Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $119.35 Million | 43.86% |
| Total Liquid Assets | $119.35 Million | 43.86% |
Asset Resilience Insights
- Very High Liquidity: Seer Inc maintains exceptional liquid asset reserves at 43.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Seer Inc Industry Peers by Asset Resilience Ratio
Compare Seer Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Seer Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Seer Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.82% | $138.61 Million | $296.08 Million | -6.56pp |
| 2024-12-31 | 53.37% | $195.66 Million | $366.60 Million | -11.66pp |
| 2023-12-31 | 65.03% | $283.73 Million | $436.27 Million | -10.39pp |
| 2022-12-31 | 75.43% | $368.03 Million | $487.93 Million | +44.40pp |
| 2021-12-31 | 31.02% | $167.26 Million | $539.14 Million | +8.80pp |
| 2020-12-31 | 22.22% | $98.28 Million | $442.32 Million | -51.29pp |
| 2019-12-31 | 73.51% | $68.53 Million | $93.24 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $33.70 Million | -- |
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis … Read more